Status:

COMPLETED

Study Evaluating Renal Cell Carcinoma Risk Factors

Lead Sponsor:

Pfizer

Conditions:

Carcinoma, Renal Cell

Eligibility:

All Genders

18+ years

Brief Summary

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patien...

Detailed Description

invitation to volunteer

Eligibility Criteria

Inclusion

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
  • Patients with other neoplasias different from RCC (current or past).

Key Trial Info

Start Date :

May 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2011

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT00927043

Start Date

May 1 2009

End Date

September 1 2011

Last Update

November 7 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pfizer Investigational Site

Pamplona, Navarre, Spain, 31008

Study Evaluating Renal Cell Carcinoma Risk Factors | DecenTrialz